WD-1603 PK Study Under Fasting and Fed Conditions in Healthy Subjects

Phase 1

• Conditions: Parkinson Disease
• Interventions: Drug: WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS

• Registration Number: NCT04513340
• Lead Sponsor: Hong Kong WD Pharmaceutical Co., Limited

Brief Summary

The Phase 1 PK study is planned to evaluate the food effect on WD-1603 pharmacokinetics

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-08-12
• Study First Submitted QC: 2020-08-12
• Study Start: 2020-08-13
• Study First Posted: 2020-08-14
• Status Verified: 2020-09
• Primary Completion: 2020-09-05
• Last Update Submitted: 2020-09-09
• Last Update Posted: 2020-09-10
• Study Completion: 2021-02-13

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 8

Inclusion Criteria

1. Normal, healthy adult human volunteers between 18 to 45 years of age (both inclusive).
2. Having a Body Mass Index (BMI) between 18.5 to 29.9 (both inclusive), calculated as weight in kg / height in m2.
3. Not having any significant disease or clinically significant abnormal findings during screening, medical history, clinical examination, laboratory evaluations, 12- lead ECG and X-ray chest (P/A view) recordings.
4. Able to understand and comply with the study procedures, in the opinion of the principal investigator.
5. Able to give voluntary written informed consent for participation in the trial.
6. In case of female subjects:

a. Surgically sterilized at least 6 months prior to study participation or If of child bearing potential is willing to use a suitable and effective double barrier contraceptive method or intra uterine device during the study.

And b. Serum Pregnancy test must be negative.

Exclusion Criteria

1. Known hypersensitivity or idiosyncratic reaction to Carbidopa or Levodopa or any of the excipients or any related drug.

2. History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.

3. Ingestion of a medicine (prescribed & over the counter (OTC) medication including herbal remedies) at any time within 14 days before dosing in Period I. In any such case subject selection will be at the discretion of the Principal Investigator.

4. Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAIDs induced urticaria.

5. Use of any recreational drugs or history of drug addiction or testing positive in pre-study drug scans.

6. A recent history of harmful use of alcohol (less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week for men and more than 7 standard drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to dosing in Period I.

7. Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from smoking during the study.

8. The presence of clinically significant abnormal laboratory values during screening.

9. History or presence of psychiatric disorders.

10. A history of difficulty in donating blood.

11. Donation of blood (1 unit or 350 mL) within a period of 90 days prior to the first dose of study medication.

12. Receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication**.

    ** If investigational medicinal product is received within 90 days where there is no blood loss except safety lab testing, subject can be included considering 10 half-lives duration of investigational medicinal product received.

13. A positive hepatitis screen including hepatitis B surface antigen and/or HCV antibodies.

14. A positive test result for HIV (1 &/or 2) antibody.

15. An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to receiving the study medicine in period I. In any such case subject selection will be at the discretion of the Principal Investigator.

16. Consumption of grapefruit or grapefruit products within 72 hours prior to dosing in period-I.

17. Difficulty in swallowing oral solid dosage form like tablets or capsules.

18. Nursing mothers (females).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Treatment A	WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS	Treatment A will be given under fed conditions by intra-oral single dose administration
Treatment B	WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS	Treatment B will be given intra-orally and orally under fed conditions by single dose administration
Treatment C	WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS	Treatment C will be given orally under fed conditions by single dose administration
Treatment D	WD-1603 CARBIDOPA and LEVODOPA EXTENDED-RELEASE TABLETS	Treatment D will be given orally under fasting conditions by single dose administration

Primary Outcome Measures

Name	Time	Method
Cmax	Day 1 and Day 2	Pharmacokinetics Measurements to Determine Cmax for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations
AUC0-∞	Day 1 and Day 2	Pharmacokinetics Measurements to Determine AUC0-∞ for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations
AUC0-t	Day 1 and Day 2	Pharmacokinetics Measurements to Determine AUC0-t for Carbidopa (CD) and Levodopa (LD) Plasma Concentrations

Secondary Outcome Measures

Name	Time	Method
Tmax	Day 1 and Day 2	Pharmacokinetics Measurements to Determine Tmax for Carbidopa (CD) and
t1/2	Day 1 and Day 2	Pharmacokinetics Measurements to Determine t1/2 for Carbidopa (CD) and

Trial Locations

Locations (1)

Lambda Therapeutic Research Ltd.; 🇮🇳 Ahmedabad, India